CAS: 760937-92-6; ((2S,4S)-4-(4-(3-Methyl-1-Phenyl-1H-Pyrazol-5-yl)Piperazin-1-yl)Pyrrolidin-2-yl)(Thiazolidin-3-yl)Methanone

该化合物是一种口服抗血球激素剂,属于二类糖尿病抑制剂(DPP-4),主要用于管理二类糖尿病,其作用机制包括抑制DPP-4酶,这导致增加胰岛素激素的含量,从而增强胰岛素分泌,并减少以依赖葡萄糖的方式释放的凝胶.这导致改进了血糖控制.Teneligliciptin的特点是化学配方,包括碳,氢,氮和氧原子的具体安排,有助于其药理特性.它通常通过口头管理,以其有利的安全性特征和低缺血病风险而著称.此外,人们注意到,丁烯酸脂在糖尿病患者的体重管理和心血管健康方面的潜在好处.对于任何药物来说,都有必要考虑潜在的副作用和抗药性,因此应该在医疗监督下使用.

结构式图片

上下游产品

1-1(2S,4S)-4-(4-(3-Methyl-1-Phenyl-1H-Pyrazol-5-yl)Piperazin-1-yl)-2-(1,3-Thiazolidin-3-Ylcarbonyl)Pyrrolidin-1-Yl Ethanone
(2S,4S)-4-[4-(3-甲基-1-苯基-1H-吡唑-5-基)-1-哌嗪]-2-(3-噻唑啉基羰基)-1-吡咯烷羧酸, 1,1-二甲基乙酯 Tert-Butyl (2S)-4-[4-(3-Methyl-1-Phenyl-1H-Pyrazol-5-yl)Piperazin-1-Yl]-2-(1,3-Thiazolidin-3-Ylcarbonyl)Pyrrolidine-1-Carboxylate 401566-80-1
1-(3-甲基-1-苯基-1H-吡唑-5-基)哌嗪 1-(3-Methyl-1-Phenyl-1H-Pyrazol-5-yl)Piperazine 401566-79-8
1-Tert-Butoxycarbonyl-4-(3-Methyl-1-Phenyl-1H-Pyrazol-5-yl)Piperazine
Tert-Butyl-4-(4-Formyl-3-Methyl-1-Phenyl-1H-Pyrazol-5-yl)Piperazine-1-Carboxylate

合成工艺路线路线简述

  • 合成目标产物 Teneligliptin 主要起始原料 (2S,4S)-4-[4-(3-Methyl-1-Phenyl-1H-Pyrazol-5-yl)-1-Piperazinyl]-2-(3-Thiazolidinylcarbonyl)-1-Pyrrolidinecarboxylic Acid Tert-Butyl Ester
  • (文献来源)合成步骤主要原料 (2S,4S)-4-[4-(3-Methyl-1-Phenyl-1H-Pyrazol-5-yl)-1-Piperazinyl]-2-(3-Thiazolidinylcarbonyl)-1-Pyrrolidinecarboxylic Acid Tert-Butyl Ester
9H-Fluoren-9-Ylmethyl (2S,4S)-4-[4-(5-Methyl-2-Phenylpyrazol-3-yl)Piperazin-1-Yl]-2-(1,3-Thiazolidine-3-Carbonyl)Pyrrolidine-1-Carboxylate置于哌啶体系中,用 二氯甲烷 作为反应溶剂,以10.5 G的收率获得产物特力利汀
参考文献:Process For The Preparation Of Teneligliptin
标题:Process For The Preparation Of Teneligliptin
摘要:一种制备替格列奉的方法.

海关参考信息

专利信息


专利号:US-10005720-B2
优先权日:2013-04-05
标题:Compounds useful for the treatment of metabolic disorders and synthesis of the same
发明人:SEXTON JONATHAN Z; BRENMAN JAY E; MUSSO DAVID L
权利人:NORTH CAROLINA CENTRAL UNIV; UNIV NORTH CAROLINA CHAPEL HILL
摘要:The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.

专利号:US-11466046-B2
优先权日:2014-10-08
标题 :14-membered ketolides and methods of their preparation and use
发明人:MYERS ANDREW G; SEIPLE IAN BASS; ZHANG ZIYANG
权利人:HARVARD COLLEGE
摘要:Provided herein are methods of preparing new 14-membered ketolides via coupling of an eastern and western half moiety, followed by macrocyclization, and optional functionalization. Intermediates in the synthesis of these ketolides including the eastern and western halves are also provided. Pharmaceutical compositions and methods of treating infectious diseases and inflammatory conditions using these ketolides are also provided.

专利号:US-2012095211-A1
优先权日:2010-09-22
标 题 :Substituted proline inhibitors of hepatitis c virus replication
发明人:BUCKMAN BRAD; NICHOLAS JOHN B; SEREBRYANY VLADIMIR; SEIWERT SCOTT D
权利人:BUCKMAN BRAD; NICHOLAS JOHN B; SEREBRYANY VLADIMIR; SEIWERT SCOTT D; INTERMUNE INC
摘要:The embodiments provide compounds of the general Formulae I, Ia, II, IIa, III, IIIa, IIIb, IV, IVa, IVb, V, Va, Vb, VI, VIa, VIb, and VIc, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. The embodiments also provide methods for the synthesis of subject compounds and intermediates in the synthetic methods.

专利号:US-7595326-B2
优先权日:2005-04-18
标题 :Synthesis of novel tubulin polymerization inhibitors: benzoylphenylurea (BPU) sulfur analogs
发明人:KHAN SAEED R; HALLUR GURULINSAPPA; HIDALGO MANUEL; JIMENO ANTONIO
权利人:CHAMPIONS BIOTECHNOLOGY INC
摘要:A novel series of BPU analogues were synthesized and evaluated for antitumor activity. In particular, BPU sulfur analogues 6 n and 7 d were shown to possess up to 10-fold increased potency, when compared to compound 1, against cancer cell lines. 6 n was more effective than compound 1 in causing apoptosis of MCF-7 cells. When compared to other drugs with a similar mechanism of action, 6 n retained significant ability to inhibit tubulin assembly, with an IC 50 of 2.1 μM.

专利号:US-7125986-B2
优先权日:1997-12-29
标题:Penicillanic acid derivative compounds and methods of making
发明人:BUYNAK JOHN D; RAO AKIREDDY SRINIVASA; DOPPALAPUDI VENKATA RAMANA
权利人:UNIV SOUTHERN METHODIST
摘要:Compounds of formula I: n nwherein R 1 , R 2 , R 3 , R 4 and n have any of the values defined in the specification, and their pharmaceutically acceptable salts, are useful for inhibiting β-lactamase enzymes, for enhancing the activity of β-lactam antibiotics, and for treating β-lactam resistant bacterial infections in a mammal. The invention also provides pharmaceutical compositions, processes for preparing compounds of formula I, and novel intermediates useful for the synthesis of compounds of formula I.

专利号:US-9422321-B2
优先权日:2010-09-07
标题 :Pyrimidine nucleoside derivatives, synthesis methods and uses thereof for preparing anti-tumor and anti-virus medicaments
发明人:CHANG JUNBIAO; AN HAOYUN; YU XUEJUN; GUO XIAOHE
权利人:CHANG JUNBIAO; AN HAOYUN; YU XUEJUN; GUO XIAOHE; HIGH & NEW TECH RES CENTER HENAN ACAD OF SCIENCES; ZHENGZHOU GRANLEN PHARMATECH LTD; UNIV ZHENGZHOU
摘要:The present invention relates to the field of pharmacochemistry. Disclosed are fluorinated and azido-substituted pyrimidine nucleoside derivatives, particularly compounds of the formula shown below: n nAlso disclosed are methods of preparation and uses for these compounds. The compounds can be used for preparing medicaments for treating diseases such as tumors and viral infections, and can be used separately or in combination with other medicaments. The compounds also have effective activity against diseases such as tumors and viral infections, while having few side effects, and thus have potential application value.
台州嘉诺华生物科技有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.canova.com.cn
企业联系电话:0576-81122208、81101151👤
📞台州嘉诺华生物科技有限公司 ⚠️参考联系方式

电话:0576-81122208、81101151

传真:0576-81122207
邮箱:canova@canova.com.cn
通信地址: 台州市黄岩区西城街道县前社区塔院头路76号
邮编:
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:台州市黄岩区西城街道县前社区塔院头路76号
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
成都宇洋高科技发展有限责任公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.yygk.com
电话: 0086-28-61777709👤
📞成都宇洋高科技发展有限责任公司 ⚠️参考联系方式

销售电话:0086-28-61777709
邮箱:yygk@yygk.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
杭州德普精细化工有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.depewchem.com
电话: 86-571-87630650👤
📞杭州德普精细化工有限公司 ⚠️参考联系方式

销售电话:86-571-87630650
邮箱:sales@depewchem.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
济南海萨新材料科技有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.highscichem.cn
企业联系电话:0531-88671759 13953109693👤
📞济南海萨新材料科技有限公司 ⚠️参考联系方式
联系人:孙经理
电话:0531-88671759 13953109693
手机:13953109693

邮箱:865641524@qq.com
通信地址: 山东省济南市高新区正丰路6号环保科技园C座1楼1021室
邮编: 250000
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:山东省济南市高新区正丰路6号环保科技园C座1楼1021室
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
台州沃德凯化工原料有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.chinaworldchem.com
企业联系电话:0576-85301198👤
📞台州沃德凯化工原料有限公司 ⚠️参考联系方式
联系人:张先生
电话:0576-85301198
手机:13736201658
传真:0576-85308398
邮箱:sales@chinaworldchem.com
通信地址: 浙江省临海市巾山东路望江银座2单元1001
邮编: 317000
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:浙江省临海市巾山东路望江银座2单元1001
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页
现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Wang G, Fu J, Li X, Wang J, Zhai J, Du B. Comparative efficacy and safety of dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes mellitus: A network meta-analysis. Diabetes Obes Metab. 2024 Dec 6. doi: 10.1111/dom.16114. Epub ahead of print. 13(22):1857. doi: 10.3390/cells13221857.
4: Shimoda M, Katakura Y, Mashiko A, Iwamoto M, Nakanishi S, Anno T, Kawasaki F, Obata A, Fushimi Y, Sanada J, Kohara K, Isobe H, Iwamoto Y, Hirukawa H, Tatsumi F, Kimura Y, Kimura T, Mune T, Kaku K, Kaneto H. Comparison of protective effects of teneligliptin and luseogliflozin on pancreatic β-cell function: randomized, parallel-group, multicenter, open-label study (SECRETE-I study). Front Endocrinol (Lausanne). 2024 Oct 21;15:1412553. doi: 10.3389/fendo.2024.1412553.
5: Guo J, Cao Y, Wu QY, Cen LS. Potential mechanism of teneligliptin in the treatment of diabetic cardiomyopathy. World J Diabetes. 2024 Oct 15;15(10):2002-2005. doi: 10.4239/wjd.v15.i10.2002.

合成参考文献


参考文献:10.1186/1475-2840-13-96
摘要:Hibuse T, Maeda N, Kishida K, Kimura T, Minami T, Takeshita E, Hirata A, Nakagawa Y, Kashine S, Oka A, Hayashi M, Nishizawa H, Funahashi T, Shimomura I. A pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus- a randomized controlled trial START-J study. Cardiovascular Diabetology. 2014 May 24;13(1):96. doi: 10.1186/1475-2840-13-96.
参考文献:10.1007/s40261-015-0348-9
摘要:Scott LJ. Teneligliptin: a review in type 2 diabetes. Clin Drug Investig. 2015 Nov;35(11):765–72. doi: 10.1007/s40261-015-0348-9.
参考文献:10.1007/s10822-017-0009-6
摘要:Cai J, Li C, Liu Z, Du J, Ye J, Gu Q, Xu J. Predicting DPP-IV inhibitors with machine learning approaches. Journal of Computer-Aided Molecular Design. 2017 Feb 02;31(4):393–402. doi: 10.1007/s10822-017-0009-6.
参考文献:10.1007/s13300-020-00880-4
摘要:Ghosh S, Tiwaskar M, Chawla R, Jaggi S, Asirvatham A, Panikar V. Teneligliptin Real-World Effectiveness Assessment in Patients with Type 2 Diabetes Mellitus in India: A Retrospective Analysis (TREAT-INDIA 2). Diabetes Therapy. 2020 Aug 11;11(10):2257–68. doi: 10.1007/s13300-020-00880-4.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知